AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9863076
Drug: Shuxuening (SXN)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shuxuening (SXN) 120 mg three times daily
Trial: 8181219
Drug: tiapride (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tiapride (200 mg/die)
Trial: 23838501
Drug: Topical diltiazem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical diltiazem gel (2ml of 2% topical diltiazem gel)
Trial: 14664471
Drug: Glatiramer acetate
RxNorm normalized name: Glatiramer Acetate
DrugBank: Glatiramer (DB05259)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glatiramer acetate (GA), 20 mg daily subcutaneous injections
Trial: 11094039
Drug: SR90107A/ORG31540 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SR90107A/ORG31540 (5 mg once daily)
Trial: 11094039
Drug: SR90107A/ORG31540 (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SR90107A/ORG31540 (7.5 mg once daily)
Trial: 11094039
Drug: SR90107A/ORG31540 (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SR90107A/ORG31540 (10 mg once daily)
Trial: 11094039
Drug: Dalteparin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dalteparin (100 IU/kg twice daily)
Trial: 8747098
Drug: Diet-oriented treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet-oriented treatment
Trial: 6624809
Drug: Picenadol (LY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Picenadol (LY 150720), 25 mg
Trial: 510179
Drug: Meperidine, 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Meperidine, 100 mg
Trial: 29716398
Drug: Context of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Context of treatment (research vs community)
Trial: 20812879
Drug: Pregabalin (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin (300 and 450 mg/day)
Trial: 15868384
Drug: Aprinocarsen (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprinocarsen (2 mg/kg continuous iv infusion on days 1-14, every 21 days) + Gemcitabine (1250 mg/m2 on days 1 and 8) + Cisplatin (80 mg/m2 on day 1)
Trial: 15868384
Drug: Gemcitabine (1250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine (1250 mg/m2 on days 1 and 8) + Cisplatin (80 mg/m2 on day 1)
Trial: 10506601
Drug: Induction therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction therapy with AFM
Trial: 8966143
Drug: Captopril (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (50 mg once daily)
Trial: 27069360
Drug: Puer tea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Puer tea extract (PTE) 3 g/day
Trial: 25043321
Drug: Basic body
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Basic body awareness therapy (BBAT) (10 weeks)
Trial: 22483196
Drug: Learning therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Learning therapy (reading aloud and solving simple calculations)
Trial: 18094894
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive with placebo (levonorgestrel and ethinyl estradiol)
Trial: 18094894
Drug: Oral contraceptive
RxNorm normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral contraceptive with estriol (levonorgestrel and ethinyl estradiol)
Trial: 9917438
Drug: Amoxicillin (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin (750 mg once daily)
Trial: 9917438
Drug: Penicillin V
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin V (250 mg three times a day)
Trial: 25304727
Drug: Low-dose interleukin-2
RxNorm normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-dose interleukin-2 (IL-2) + interferon-α (IFN-α)
Trial: 22789797
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (calcium-channel blockers or angiotensin converting enzyme inhibitors)
Trial: 15499224
Drug: 3-month formulation
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3-month formulation
Trial: 15499224
Drug: 28-day formulation
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 28-day formulation
Trial: 2846480
Drug: Superfractionated radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Superfractionated radiation (3 times a day to a total dose of 4760 cGy)
Trial: 2846480
Drug: Standard daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard daily treatment (to 4000 cGy)
Trial: 2846480
Drug: Standard daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard daily treatment
Trial: 4919554
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (Cyclokapron) 1 g four times a day for the first four days of menstruation
Trial: 28357598
Drug: Superficial dentin
RxNorm normalized name: benzocaine
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Superficial dentin groups (all treatments)
Trial: 23803136
Drug: Clopidogrel (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (300 mg initial dose, followed by 75 mg/day for 90 days) plus aspirin (75 mg/day for 21 days)
Trial: 23803136
Drug: Aspirin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (75 mg/day for 90 days)
Trial: 23803136
Drug: Clopidogrel-aspirin group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel-aspirin group
Trial: 21693699
Drug: Ezetimibe/simvastatin 10
RxNorm normalized name: Ezetimibe/Simvastatin 10 MG-10 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe/simvastatin 10 mg/20 mg in the morning (within 1 hour of breakfast)
Trial: 21693699
Drug: Ezetimibe/simvastatin 10
RxNorm normalized name: Ezetimibe/Simvastatin 10 MG-10 MG Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ezetimibe/simvastatin 10 mg/20 mg in the evening (within 1 hour of dinner)
Trial: 18300746
Drug: Glucose-insulin-potassium (GIK)
RxNorm normalized name: glucose / potassium chloride
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose-insulin-potassium (GIK) treatment
Trial: 16608780
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TA) 0.75 g loading dose before surgery and 250 mg/h during surgery (total 1.5 g)
Trial: 16608780
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (TA) and Saline solution (control)
Trial: 14600575
Drug: Intermittent interleukin-2
RxNorm normalized name: Interleukin-2 aldesleukin
DrugBank: Aldesleukin (DB00041)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent interleukin-2 (IL-2) therapy
Trial: 12847572
Drug: Doxazosin standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin standard formulation
Trial: 8782296
Drug: Kurume solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kurume solution with 1% albumin (group 2)
Trial: 8782296
Drug: GIK solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GIK solution with 1% albumin (group 4)
Trial: 8782296
Drug: Kurume solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kurume solution without albumin (group 1)
Trial: 8782296
Drug: GIK solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GIK solution without albumin (group 3)
Trial: 6148872
Drug: Nadolol (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nadolol (mean dosage, 87 +/- 43 mg/day)
Trial: 27093774
Drug: Skilled operator
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Skilled operator using one-step self-etch (G-Bond)
Trial: 27093774
Drug: Unexperienced operators
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unexperienced operators using one-step self-etch (G-Bond)
Trial: 12368364
Drug: Spironolactone (12.5-50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (12.5-50 mg/day)
Trial: 7862911
Drug: Milacemide (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Milacemide (400 mg)
Trial: 322921
Drug: Carbidopa (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbidopa (100 mg/day for 6 weeks)
Trial: 24704626
Drug: Fenofibric acid
RxNorm normalized name: Fenofibric Acid
DrugBank: Fenofibric acid (DB13873)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibric acid (FA) therapy alone
Trial: 24704626
Drug: Fenofibric acid
RxNorm normalized name: Fenofibric Acid
DrugBank: Fenofibric acid (DB13873)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenofibric acid (FA) and statin therapy
Trial: 24704626
Drug: Statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Statin therapy alone
Trial: 18418975
Drug: Egb761 (Ginkgo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Egb761 (Ginkgo biloba extract) with chemotherapy (4 cycles of PA protocol)
Trial: 16192262
Drug: Diet enriched
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet enriched with probiotics (6 x 10^9 CFU of Streptococcus thermophilus, Bifidobacterium lactis, Lactobacillus acidophilus) and 10 mg of zinc/day
Trial: 12814810
Drug: Yasmin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Yasmin (30 microg ethinylestradiol and 3 mg drospirenone)
Trial: 1731027
Drug: Antibiotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic therapy with bacteriologic efficacy of 100%
Trial: 1731027
Drug: Antibiotic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic therapy with bacteriologic efficacy of 27% (consistent with no antibacterial therapy)
Trial: 1731027
Drug: Tympanocentesis and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tympanocentesis and culture before and during therapy
Trial: 1731027
Drug: Tympanocentesis before
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tympanocentesis before therapy and assessment of clinical efficacy
Trial: 22994106
Drug: Intravenous mexidol
RxNorm normalized name: Brexidol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous mexidol (300 mg daily for 2 weeks)
Trial: 22994106
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment of primary open-angle glaucoma
Trial: 20038730
Drug: Platinum-doublet chemotherapy
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum-doublet chemotherapy for three cycles followed by gefitinib 250 mg orally once daily, until disease progression (arm B)
Trial: 20038730
Drug: Platinum-doublet chemotherapy
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum-doublet chemotherapy up to six cycles (arm A)
Trial: 20038730
Drug: Platinum-doublet chemotherapy
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum-doublet chemotherapy for three cycles followed by gefitinib 250 mg orally once daily (arm B)
Trial: 17572319
Drug: Ropivacaine 0.2%
RxNorm normalized name: ROPivacaine 0.2% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.2% (500 mg in 48 hours via elastomeric pump)
Trial: 17572319
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (250 mL as placebo)
Trial: 16175565
Drug: Treatment for
RxNorm normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Treatment for SAD (exact intervention details not specified)
Trial: 16175565
Drug: Nonresponders to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonresponders to treatment
Trial: 2884856
Drug: Doxazosin 12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin 12 mg (range 1 to 16)
Trial: 2884856
Drug: Atenolol 91.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 91.8 mg (range 50 to 100)
Trial: 18156639
Drug: 17beta‐estradiol for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17beta‐estradiol for replacement therapy
Trial: 12218723
Drug: EMTDS 0.025
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMTDS 0.025 mg/day
Trial: 12218723
Drug: EMTDS 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMTDS 0.05 mg/day
Trial: 12218723
Drug: EMTDS 0.075
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMTDS 0.075 mg/day
Trial: 9468457
Drug: Angiotensin II
RxNorm normalized name: Angiotensin II
DrugBank: Angiotensin II (DB11842)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Angiotensin II infusion (2 ng Ang II/kg per min)
Trial: 8194508
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg elemental zinc (as zinc sulphate) for 7 days
Trial: 8194508
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg elemental zinc (as zinc sulphate) for 7 days
Trial: 11171824
Drug: Duodenal lipid
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duodenal lipid infusion (L-2)
Trial: 11171824
Drug: CCK-A antagonist
RxNorm normalized name: CCK-8
DrugBank: Sincalide (DB09142)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CCK-A antagonist dexloxiglumide (5 mg/kg/h)
Trial: 30249507
Drug: Ustekinumab (260
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ustekinumab (260 mg for patients weighing 35-55 kg, 390 mg for patients weighing >55 kg and ≤85 kg, and 520 mg for patients weighing >85 kg) followed by subcutaneous injections of 90 mg every 8 weeks.
Trial: 30249507
Drug: Placebo intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo intravenous infusion at week 0 followed by subcutaneous injections every 8 weeks.
Trial: 25407020
Drug: Same-day opioid
RxNorm normalized name: SAMe
DrugBank: Ademetionine (DB00118)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Same-day opioid substitution treatment (methadone)
Trial: 25407020
Drug: Regular health
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular health evaluation paired with low-barrier access to treatment
Trial: 18035193
Drug: Risedronate 5
RxNorm normalized name: risedronate 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risedronate 5 mg PO QD for 24 months
Trial: 16303729
Drug: Benazepril alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benazepril alone (higher dose)
Trial: 16303729
Drug: Losartan alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan alone (higher dose)
Trial: 7629898
Drug: Oral buffered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral buffered deferoxamine solution (5 mg/kg elemental iron)
Trial: 7629898
Drug: Control phase
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control phase (5 mg/kg elemental iron alone)
Trial: 779516
Drug: Maltose treatment
RxNorm normalized name: Maltose
DrugBank: Maltose (DB03323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maltose treatment (drinks sweetened with maltose 2 hours before operation)
Trial: 30879908
Drug: Warmed intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warmed intravenous fluid group
Trial: 25925033
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine (3mg/kg infused over 1h)
Trial: 19629674
Drug: GnRH agonist
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GnRH agonist (leuprolide acetate 0.15 mg)
Trial: 16984503
Drug: MMX mesalazine
RxNorm normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MMX mesalazine 1.2 g/day
Trial: 31470599
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg of non-animal chondroitin sulfate daily for 12 weeks
Trial: 20921313
Drug: Raltegravir with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raltegravir with antacid
Trial: 31925185
Drug: Genetically predicted
RxNorm normalized name: Burosumab (genetical recombination)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Genetically predicted insulin (per pmol/L higher insulin)
Trial: 28449232
Drug: 0.35 mg
RxNorm normalized name: nicotine 0.35 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.35 mg GSK2881078 (in women)
Trial: 28449232
Drug: 0.05 mg,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg, 0.2 mg, 0.08 mg, 0.24 mg, 0.48 mg, 0.75 mg GSK2881078 (in men)
Trial: 20017932
Drug: ACEI (Quinapril)
RxNorm normalized name: Veneno de Abeja Aceite de Vibora
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACEI (Quinapril) or Statins (Atorvastatin) or combination therapy
Trial: 15152893
Drug: Montelukast (CysLTs
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Montelukast (CysLTs type‐1 receptor antagonist)
Trial: 11700185
Drug: Granular formulation
RxNorm normalized name: Saxifraga granulata whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granular formulation of the insect growth regulator pyriproxyfen at a target dose of 0.01 mg a.i./litre
Trial: 11700185
Drug: Granular formulation
RxNorm normalized name: Saxifraga granulata whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granular formulation of the insect growth regulator pyriproxyfen
Trial: 8197772
Drug: Continuous hyperthermic
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous hyperthermic peritoneal perfusion (CHPP) with cisplatin (CDDP) 300 mg/kg and mitomycin C (MMC) 30 mg/kg
Trial: 8197772
Drug: Continuous normothermic
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous normothermic peritoneal perfusion (CNPP) with cisplatin (CDDP) 300 mg/kg and mitomycin C (MMC) 30 mg/kg
Trial: 2839628
Drug: Enalapril 10
RxNorm normalized name: enalapril 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril 10 mg twice daily (n = 16)
Trial: 2839628
Drug: Hydrochlorothiazide 25
RxNorm normalized name: hydrochlorothiazide 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 25 mg twice daily (n = 15)
Trial: 2839628
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (10 mg enalapril and 25 mg hydrochlorothiazide twice daily, n = 6)
Trial: 2839628
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy after 8 additional weeks
Trial: 2839628
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy after one year
Trial: 4937034
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of 10% lignocaine
Trial: 31780025
Drug: Curcumin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin (500 mg/d)
Trial: 19019444
Drug: Initial medicine
RxNorm normalized name: Medicaine Sting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial medicine
Trial: 7944835
Drug: Active antihypertensive
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active antihypertensive drug therapy (12.5 to 25 mg of chlorthalidone for step 1; 25 to 50 mg of atenolol for step 2; or 0.05 to 0.10 mg of reserpine if atenolol was contraindicated)
Trial: 3065740
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose continuous chlorambucil (regimen A)
Trial: 30352838
Drug: Fenretinide 200
RxNorm normalized name: FENRETINIDE
DrugBank: Fenretinide (DB05076)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenretinide 200 mg daily
Trial: 30352838
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Tamoxifen and Fenretinide
Trial: 12173362
Drug: Erythromycin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (200 mg intravenously) during normoglycemia
Trial: 12173362
Drug: Erythromycin (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (200 mg intravenously) during hyperglycemia
Trial: 10592403
Drug: Liquor carbonis
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liquor carbonis detergens (tar preparation)
Trial: 1656738
Drug: Azithromycin 500
RxNorm normalized name: azithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 500 mg once on day 1 followed by 250 mg once daily for 4 days
Trial: 1656738
Drug: Penicillin V
RxNorm normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Penicillin V 250 mg every 6 hours for 10 days
Trial: 27067478
Drug: Riociguat (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Riociguat (2.5 mg three times per day)